A phage-targeting strategy for the design of spatiotemporal drug delivery from grafted matrices

Fibrogenesis and Tissue Repair

Volumn 4, Issue 1, 2011, Pages

  Sawada, Ritsuko ^a,b   Peterson, Carrie Y ^a   Gonzalez, Ana Maria ^c   Potenza, Bruce M ^a   Mueller, Barbara ^d   Coimbra, Raul ^a   Eliceiri, Brian P ^a   Baird, Andrew ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MabVax Therapeutics Inc   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952329270     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-4-7     Document Type: Article

References (67)

1. Chan ES, Lam PK, Liew CT, Lau HC, Yen RS, King WW. A new technique to resurface wounds with composite biocompatible epidermal graft and artificial skin. J Trauma 2001, 50:358-362. 10.1097/00005373-200102000-00028, 11242307.
2. Clayman MA, Clayman SM, Mozingo DW. The use of collagen-glycosaminoglycan copolymer (Integra®) for the repair of hypertrophic scars and keloids. J Burn Care Res 2006, 27:404-409. 10.1097/01.BCR.0000216749.72080.89, 16679913.
3. Gravvanis AI, Tsoutsos DA, Iconomou T, Gremoutis G. The use of integra® artificial dermis to minimize donor-site morbidity after suprafascial dissection of the radial forearm flap. Microsurgery 2007, 27:583-587. 10.1002/micr.20406, 17868139.
4. Mis B, Rolland E, Ronfard V. Combined use of a collagen-based dermal substitute and a fibrin-based cultured epithelium: a step toward a total skin replacement for acute wounds. Burns 2004, 30:713-719. 10.1016/j.burns.2004.04.007, 15475148.
5. Schneider J, Biedermann T, Widmer D, Montano I, Meuli M, Reichmann E, Schiestl C. Matriderm versus Integra®: a comparative experimental study. Burns 2009, 35:51-57. 10.1016/j.burns.2008.07.018, 18951720.
6. Chen RR, Silva EA, Yuen WW, Brock AA, Fischbach C, Lin AS, Guldberg RE, Mooney DJ. Integrated approach to designing growth factor delivery systems. FASEB J 2007, 21:3896-3903. 10.1096/fj.06-7873com, 17644610.
7. Hall H. Modified fibrin hydrogel matrices: both, 3D-scaffolds and local and controlled release systems to stimulate angiogenesis. Curr Pharm Des 2007, 13:3597-3607. 10.2174/138161207782794158, 18220797.
8. Huang S, Fu X. Naturally derived materials-based cell and drug delivery systems in skin regeneration. J Control Release 2009,
9. Silva EA, Mooney DJ. Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 2007, 5:590-598. 10.1111/j.1538-7836.2007.02386.x, 17229044.
10. Wilcke I, Lohmeyer JA, Liu S, Condurache A, Kruger S, Mailander P, Machens HG. VEGF(165) and bFGF protein-based therapy in a slow release system to improve angiogenesis in a bioartificial dermal substitute in vitro and in vivo. Langenbecks Arch Surg 2007, 392:305-314. 10.1007/s00423-007-0194-1, 17404752.
11. Zisch AH, Zeisberger SM, Ehrbar M, Djonov V, Weber CC, Ziemiecki A, Pasquale EB, Hubbell JA. Engineered fibrin matrices for functional display of cell membrane-bound growth factor-like activities: study of angiogenic signaling by ephrin-B2. Biomaterials 2004, 25:3245-3257. 10.1016/j.biomaterials.2003.10.015, 14980419.
12. Cao L, Mooney DJ. Spatiotemporal control over growth factor signaling for therapeutic neovascularization. Adv Drug Deliv Rev 2007, 59:1340-1350. 10.1016/j.addr.2007.08.012, 2581871, 17868951.
13. Halstenberg S, Panitch A, Rizzi S, Hall H, Hubbell JA. Biologically engineered protein-graft-poly(ethylene glycol) hydrogels: a cell adhesive and plasmin-degradable biosynthetic material for tissue repair. Biomacromolecules 2002, 3:710-723. 10.1021/bm015629o, 12099815.
14. Marino P, Norreel JC, Schachner M, Rougon G, Amoureux MC. A polysialic acid mimetic peptide promotes functional recovery in a mouse model of spinal cord injury. Exp Neurol 2009, 219:163-174. 10.1016/j.expneurol.2009.05.009, 19445935.
15. Markoishvili K, Tsitlanadze G, Katsarava R, Morris JG, Sulakvelidze A. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int J Dermatol 2002, 41:453-458. 10.1046/j.1365-4362.2002.01451.x, 12121566.
16. Milleret V, Simonet M, Bittermann AG, Neuenschwander P, Hall H. Cyto- and hemocompatibility of a biodegradable 3D-scaffold material designed for medical applications. J Biomed Mater Res B Appl Biomater 2009, 91:109-121.
17. Berry M, Gonzalez AM, Clarke W, Greenlees L, Barrett L, Tsang W, Seymour L, Bonadio J, Logan A, Baird A. Sustained effects of gene-activated matrices after CNS injury. Mol Cell Neurosci 2001, 17:706-716. 10.1006/mcne.2001.0975, 11312606.
18. Gonzalez AM, Berlanga O, Leadbeater WE, Cooper-Charles L, Sims K, Logan A, Eliceiri B, Berry M, Baird A. The deployment of adenovirus-containing gene activated matrices onto severed axons after central nervous system injury leads to transgene expression in target neuronal cell bodies. J Gene Med 2009, 11:679-688. 10.1002/jgm.1354, 19507166.
19. Gonzalez AM, Berry M, Greenlees L, Logan A, Baird A. Matrix-mediated gene transfer to brain cortex and dorsal root ganglion neurones by retrograde axonal transport after dorsal column lesion. J Gene Med 2006, 8:901-909. 10.1002/jgm.919, 16718733.
20. Gu DL, Nguyen T, Gonzalez AM, Printz MA, Pierce GF, Sosnowski BA, Phillips ML, Chandler LA. Adenovirus encoding human platelet-derived growth factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical use. Mol Ther 2004, 9:699-711. 10.1016/j.ymthe.2004.02.018, 15120331.
21. Peterson CY, Shaterian A, Borboa AK, Gonzalez AM, Potenza BM, Coimbra R, Eliceiri BP, Baird A. The noninvasive, quantitative, in vivo assessment of adenoviral-mediated gene delivery in skin wound biomaterials. Biomaterials 2009, 30:6788-6793. 10.1016/j.biomaterials.2009.07.069, 2948440, 19781761.
22. Shaterian A, Borboa A, Sawada R, Costantini T, Potenza B, Coimbra R, Baird A, Eliceiri BP. Real-time analysis of the kinetics of angiogenesis and vascular permeability in an animal model of wound healing. Burns 2009, 35:811-817. 10.1016/j.burns.2008.12.012, 2739287, 19423227.
23. Calcutt NA, Jolivalt CG, Fernyhough P. Growth factors as therapeutics for diabetic neuropathy. Curr Drug Targets 2008, 9:47-59. 10.2174/138945008783431727, 18220712.
24. Undas A, Celinska-Lowenhoff M, Stepien E, Nizankowski R, Tracz W, Szczeklik A. Effects of simvastatin on angiogenic growth factors released at the site of microvascular injury. Thromb Haemost 2006, 95:1045-1047.
25. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205. 10.1200/JCO.2006.06.4451, 16682719.
26. Riedel K, Riedel F, Goessler UR, Holle G, Germann G, Sauerbier M. Current status of genetic modulation of growth factors in wound repair. Int J Mol Med 2006, 17:183-193.
27. Becker JC, Beckbauer M, Domschke W, Herbst H, Pohle T. Fibrin glue, healing of gastric mucosal injury, and expression of growth factors: results from a human in vivo study. Gastrointest Endosc 2005, 61:560-567. 10.1016/S0016-5107(05)00291-9, 15812409.
28. Goldman R. Growth factors and chronic wound healing: past, present, and future. Adv Skin Wound Care 2004, 17:24-35. 10.1097/00129334-200401000-00012, 14752324.
29. Smith PD, Polo M, Soler PM, McClintock JS, Maggi SP, Kim YJ, Ko F, Robson CM. Efficacy of growth factors in the accelerated closure of interstices in explanted meshed human skin grafts. J Burn Care Rehabil 2000, 21:5-9. 10.1097/00004630-200021010-00003, 10661532.
30. Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 1999, 14:529-535.
31. Cobb JP, Brownstein BH, Watson MA, Shannon WD, Laramie JM, Qiu Y, Stormo GD, Morrissey JJ, Buchman TG, Karl IE, Hotchkiss RS. Injury in the era of genomics. Shock 2001, 15:165-170. 10.1097/00024382-200115030-00001, 11236897.
32. Ganesan AK, Ho H, Bodemann B, Petersen S, Aruri J, Koshy S, Richardson Z, Le LQ, Krasieva T, Roth MG, et al. Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells. PLoS Genet 2008, 4:e1000298. 10.1371/journal.pgen.1000298, 2585813, 19057677.
33. Roy S, Khanna S, Yeh PE, Rink C, Malarkey WB, Kiecolt-Glaser J, Laskowski B, Glaser R, Sen CK. Wound site neutrophil transcriptome in response to psychological stress in young men. Gene Expr 2005, 12:273-287. 10.3727/000000005783992025, 16358416.
34. Tarran SL, Craft GE, Valova V, Robinson PJ, Thomas G, Markham R, Langlois NE, Vanezis P. The use of proteomics to study wound healing: a preliminary study for forensic estimation of wound age. Med Sci Law 2007, 47:134-140. 10.1258/rsmmsl.47.2.134, 17520958.
35. Jansen BJ, Schalkwijk J. Transcriptomics and proteomics of human skin. Brief Funct Genomic Proteomic 2003, 1:326-341. 10.1093/bfgp/1.4.326, 15239881.
36. Roy S, Khanna S, Rink C, Biswas S, Sen CK. Characterization of the acute temporal changes in excisional murine cutaneous wound inflammation by screening of the wound-edge transcriptome. Physiol Genomics 2008, 34:162-184. 10.1152/physiolgenomics.00045.2008, 2494843, 18460641.
37. Roy S, Patel D, Khanna S, Gordillo GM, Biswas S, Friedman A, Sen CK. Transcriptome-wide analysis of blood vessels laser captured from human skin and chronic wound-edge tissue. Proc Natl Acad Sci USA 2007, 104:14472-14477. 10.1073/pnas.0706793104, 1964861, 17728400.
38. van Ruissen F, Jansen BJ, de Jongh GJ, Zeeuwen PL, Schalkwijk J. A partial transcriptome of human epidermis. Genomics 2002, 79:671-678. 10.1006/geno.2002.6756, 11991716.
39. Kueh J, Richards M, Ng SW, Chan WK, Bongso A. The search for factors in human feeders that support the derivation and propagation of human embryonic stem cells: preliminary studies using transcriptome profiling by serial analysis of gene expression. Fertil Steril 2006, 85:1843-1846. 10.1016/j.fertnstert.2005.11.042, 16674954.
40. Edinger M, Hoffmann P, Contag CH, Negrin RS. Evaluation of effector cell fate and function by in vivo bioluminescence imaging. Methods 2003, 31:172-179. 10.1016/S1046-2023(03)00127-0, 12957575.
41. Henriquez NV, van Overveld PG, Que I, Buijs JT, Bachelier R, Kaijzel EL, Lowik CW, Clezardin P, van der Pluijm G. Advances in optical imaging and novel model systems for cancer metastasis research. Clin Exp Metastasis 2007, 24:699-705. 10.1007/s10585-007-9115-5, 17972147.
42. Shah K, Weissleder R. Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx 2005, 2:215-225. 10.1602/neurorx.2.2.215, 1064987, 15897946.
43. Smith GP, Petrenko VA. Phage Display. Chem Rev 1997, 97:391-410. 10.1021/cr960065d, 11848876.
44. Zhang N, Fang Z, Contag PR, Purchio AF, West DB. Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse. Blood 2004, 103:617-626. 10.1182/blood-2003-06-1820, 14512298.
45. Nakao A, Miike S, Hatano M, Okumura K, Tokuhisa T, Ra C, Iwamoto I. Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med 2000, 192:151-158. 10.1084/jem.192.2.151, 2193250, 10899902.
46. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002, 13:413-421. 10.1016/S1359-6101(02)00026-6, 12220554.
47. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228:1315-1317. 10.1126/science.4001944, 4001944.
48. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002, 8:121-127. 10.1038/nm0202-121, 11821895.
49. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006, 12:3200-3208. 10.1158/1078-0432.CCR-05-2804, 16707621.
50. Koivunen E, Arap W, Rajotte D, Lahdenranta J, Pasqualini R. Identification of receptor ligands with phage display peptide libraries. J Nucl Med 1999, 40:883-888.
51. Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 1993, 268:20205-20210.
52. Lee SM, Lee EJ, Hong HY, Kwon MK, Kwon TH, Choi JY, Park RW, Kwon TG, Yoo ES, Yoon GS, et al. Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol Cancer Res 2007, 5:11-19. 10.1158/1541-7786.MCR-06-0069, 17259343.
53. Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA, Trepel M. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003, 21:1040-1046. 10.1038/nbt856, 12897791.
54. Pasqualini R, Koivunen E, Ruoslahti E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol 1995, 130:1189-1196. 10.1083/jcb.130.5.1189, 2120548, 7657703.
55. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996, 380:364-366. 10.1038/380364a0, 8598934.
56. Petrenko VA, Smith GP, Mazooji MM, Quinn T. Alpha-helically constrained phage display library. Protein Eng 2002, 15:943-950. 10.1093/protein/15.11.943, 12538914.
57. Pilch J, Brown DM, Komatsu M, Jarvinen TA, Yang M, Peters D, Hoffman RM, Ruoslahti E. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci USA 2006, 103:2800-2804. 10.1073/pnas.0511219103, 1413849, 16476999.
58. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998, 102:430-437. 10.1172/JCI3008, 508902, 9664085.
59. Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 2002, 6:399-404. 10.1016/S1367-5931(02)00336-8, 12023122.
60. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol 1994, 124:373-380. 10.1083/jcb.124.3.373, 2119941, 7507494.
61. Kraft S, Diefenbach B, Mehta R, Jonczyk A, Luckenbach GA, Goodman SL. Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J Biol Chem 1999, 274:1979-1985. 10.1074/jbc.274.4.1979, 9890954.
62. Cislo M, Dabrowski M, Weber-Dabrowska B, Woyton A. Bacteriophage treatment of suppurative skin infections. Arch Immunol Ther Exp (Warsz) 1987, 35:175-183.
63. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 2009, 18:237-238. 240-233.
64. Burg MA, Jensen-Pergakes K, Gonzalez AM, Ravey P, Baird A, Larocca D. Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells. Cancer Res 2002, 62:977-981.
65. Larocca D, Jensen-Pergakes K, Burg MA, Baird A. Receptor-targeted gene delivery using multivalent phagemid particles. Mol Ther 2001, 3:476-484. 10.1006/mthe.2001.0284, 11319907.
66. Larocca D, Kassner PD, Witte A, Ladner RC, Pierce GF, Baird A. Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. FASEB J 1999, 13:727-734.
67. Kassner PD, Burg MA, Baird A, Larocca D. Genetic selection of phage engineered for receptor-mediated gene transfer to mammalian cells. Biochem Biophys Res Commun 1999, 264:921-928. 10.1006/bbrc.1999.1603, 10544031.